

3-10-05

JPAS 1644
\$

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	09/774,681-Conf. #3045
Filing Date	February 1, 2001
First Named Inventor	Linda Sherman
Art Unit	1644
Examiner Name	R. B. Schwadron
Attorney Docket Number	55793DIV(48340)

ENCLOSURES (Check all that apply)

- | | | |
|--|--|--|
| <input type="checkbox"/> Fee Transmittal Form
<input type="checkbox"/> Fee Attached
<input checked="" type="checkbox"/> Amendment/Reply (8 pages)
<input type="checkbox"/> After Final
<input type="checkbox"/> Affidavits/declaration(s)
<input type="checkbox"/> Extension of Time Request
<input type="checkbox"/> Express Abandonment Request
<input checked="" type="checkbox"/> IDS (2 pages)
<input type="checkbox"/> Certified Copy of Priority Document(s)
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Drawing(s)
<input type="checkbox"/> Licensing-related Papers
<input type="checkbox"/> Petition
<input type="checkbox"/> Petition to Convert to a Provisional Application
<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address
<input type="checkbox"/> Terminal Disclaimer
<input type="checkbox"/> Request for Refund
<input type="checkbox"/> CD, Number of CD(s) _____
<input type="checkbox"/> Landscape Table on CD | <input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Status Letter
<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
PTO/SB/08 (1 page);
13 References;
Copy of Notice of Non-Compliant Amendment (37 CFR 1.121);
Return Receipt Postcard |
|--|--|--|

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	EDWARDS & ANGELL, LLP		
Signature	<i>Kathryn A. Piffat, Ph.D.</i>		
Printed name	Kathryn A. Piffat, Ph.D.		
Date	March 8, 2005	Reg. No.	34,901

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 492 339 717 US, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: March 8, 2005

Signature: *Sharon Bizokas*

(Sharon Bizokas)



I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 492 339 717 US, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: March 8, 2005

Signature: *Sharon Bizjak*
(Sharon Bizjak)

Docket No.: 55793DIV(48340)
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Linda Sherman et al.

Application No.: 09/774,681

Confirmation No.: 3045

Filed: February 1, 2001

Art Unit: 1644

For: RECOMBINANT CONSTRUCTS
ENCODING T CELL RECEPTORS
SPECIFIC FOR HUMAN HLA-
RESTRICTED TUMOR ANTIGENS

Examiner: Schwadron, Ronald B.

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed more than three months after the U.S. filing date, OR more than three months after the date of entry of the national stage of a PCT application, AND after the mailing date of the first Office Action on the merits, whichever occurs first, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

A copy of each reference on the PTO/SB/08 is attached.

03/14/2005 JBALINAN 00000067 041105 09774681'

01 FC:1806

180.00 DA

A concise explanation of relevance of the items listed on form PTO/SB/08 is in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.


In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Please charge our Deposit Account No. 04-1105 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 55793DIV(48340). A duplicate copy of this paper is enclosed.

Dated: March 8, 2005

Respectfully submitted,

By 
Kathryn A. Piffat, Ph.D.

Registration No.: 34,901
EDWARDS & ANGELL, LLP
P.O. Box 55874
Boston, Massachusetts 02205
(617) 439-4444
Attorney for Applicant



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/774,681-Conf. #3045
				Filing Date	February 1, 2001
				First Named Inventor	Linda Sherman
				Art Unit	1644
				Examiner Name	R.B. Schwadron
Sheet	1	of	1	Attorney Docket Number	55793DIV(48340)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Danska, et al., The Presumptive CDR3 Regions of Both T Cell Receptor α and β Chains Determine T Cell Specificity for Myoglobin Peptides, J. Exp. Med., 172:27-33 (1990)	
	CB	Kodama et al., "Significance of Premature Stop Codons in <i>env</i> of Simian Immunodeficiency Virus", J. Virol. 63(11):4709-4714 (1989)	
	CC	Chang et al., "A general method for facilitating heterodimeric pairing between two proteins: Application to expression of α and β T-cell receptor extracellular segments", Proc. Natl. Acad. Sci. USA, 91:11408-11412 (1994)	
	CD	Moritz and Groner, "A spacer region between the single chain antibody and the CD3 ζ -chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity", Gene Therapy, 2:539-546 (1995)	
	CD	Disis et al., "In Vitro Generation of Human Cytolytic T-Cells Specific for Peptides Derived from the HER-2neu Protooncogene Protein ¹ ", Cancer Research, 54:1071-1076 (1994)	
	CF	Broeren et al., Conserved nucleotide sequences at the 5' end of T cell receptor variable genes facilitate polymerase chain reaction amplification", Eur. J. Immunol., 21:569-575 (1991)	
	CG	Ruppert et al., Prominent Role of Secondary Anchor Residues in Peptide Binding to HLA-A2.1 Molecules", Cell, 74:929-937 (1993)	
	CH	Tal et al., "Human HER2 (<i>neu</i>) Promoter: Evidence for Multiple Mechanisms for Transcriptional Initiation" Molecular and Cellular Biology, 7(7):2597-2601 (1987)	
	CI	Papewalis et al., "G to A polymorphism at amino acid codon 655 of the human <i>erbB-2/HER2</i> gene", Nucleic Acids Research, Vol. 19(19):5452 (1991)	
	CJ	Yamamoto et al., "Similarity of protein encoded by the human <i>c-erbB-2</i> gene to epidermal growth factor receptor", Nature, 319:230-234 (1986)	
	CK	J. Kuby, Immunology, 1992, W.H. Freeman and Company, page 519	
	CL	Mullins et al., Expression of the DBA/2J Ren-2 gene in the adrenal, The EMBO Journal, 8(13):4065-4072 (1989)	
	CM	Mullins et al., Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gen, Nature, 344:541-544 (1990)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--